Abstract
Objective: Three phase 1 clinical trials of a superpotent melanotropic peptide, metanotan-1 (MT-1, or [Nle4-D-Phe7] α-melanocyte-stimulating hormone) were performed to demonstrate safety for MT-1 therapy combined with UV-B light or sunlight. Design: Open-label studies at 2 dose levels of MT-1 combined with small doses of UV-B to the neck or buttock or full sunlight to half of the back. Setting: Dermatology clinics at the Arizona Health Sciences Center, Tucson. Interventions: The first study randomized 4 subjects to MT-1 (0.08 mg/kg per day subcutaneously) and 4 subjects to injections of isotonic sodium chloride (9%) solution for 10 days, followed by neck irradiation with 3 times the minimal erythema dose (MED) of UV-B light. In the next study (n = 12), the MT-1 dosage was increased to 0.16 mg/kg per day for 10 days, with UV-B radiation (0.25-0.75 MED) given to a buttock site for 5 days during (n = 7) or after (n = 5) MT-1 administration. A final study randomized 8 subjects to 3 to 5 days of sunlight to half of the back or to sunlight plus 0.16 mg/kg of MT-1 for 5 days per week for 4 weeks. Results. Tanning in the first study was achieved in 3 of 4 subjects receiving MT-1, and these subjects also had 47% fewer sunburn cells at the irradiated neck site. More skin sites darkened with the higher dose of MT-1 in the second study. In the third study, there was significantly enhanced tanning of the back in the MT-1 group, and this was maintained at least 3 weeks longer than the tanning in the sunlight-only controls, who required 50% more sun-exposure time for equivalent tanning. Main Outcome Measure: There were no pathologic findings at any UV-B or sun-exposed sites in any subject. Toxic effects due to MT-1 were minor, consisting of nausea and transient facial flushing. Conclusion: Melanotan-1 can be safely combined with UV-B light or sunlight and appears to act synergistically in the tanning response to light.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 827-835 |
| Number of pages | 9 |
| Journal | Archives of Dermatology |
| Volume | 140 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2004 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. / Dorr, Robert T; Ertl, Gregory; Levine, Norman; Brooks, Chris; Bangert, Jerry L.; Powell, Marianne Broome; Humphrey, Stuart; Alberts, David S.
In: Archives of Dermatology, Vol. 140, No. 7, 07.2004, p. 827-835.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers
AU - Dorr, Robert T
AU - Ertl, Gregory
AU - Levine, Norman
AU - Brooks, Chris
AU - Bangert, Jerry L.
AU - Powell, Marianne Broome
AU - Humphrey, Stuart
AU - Alberts, David S
PY - 2004/7
Y1 - 2004/7
N2 - Objective: Three phase 1 clinical trials of a superpotent melanotropic peptide, metanotan-1 (MT-1, or [Nle4-D-Phe7] α-melanocyte-stimulating hormone) were performed to demonstrate safety for MT-1 therapy combined with UV-B light or sunlight. Design: Open-label studies at 2 dose levels of MT-1 combined with small doses of UV-B to the neck or buttock or full sunlight to half of the back. Setting: Dermatology clinics at the Arizona Health Sciences Center, Tucson. Interventions: The first study randomized 4 subjects to MT-1 (0.08 mg/kg per day subcutaneously) and 4 subjects to injections of isotonic sodium chloride (9%) solution for 10 days, followed by neck irradiation with 3 times the minimal erythema dose (MED) of UV-B light. In the next study (n = 12), the MT-1 dosage was increased to 0.16 mg/kg per day for 10 days, with UV-B radiation (0.25-0.75 MED) given to a buttock site for 5 days during (n = 7) or after (n = 5) MT-1 administration. A final study randomized 8 subjects to 3 to 5 days of sunlight to half of the back or to sunlight plus 0.16 mg/kg of MT-1 for 5 days per week for 4 weeks. Results. Tanning in the first study was achieved in 3 of 4 subjects receiving MT-1, and these subjects also had 47% fewer sunburn cells at the irradiated neck site. More skin sites darkened with the higher dose of MT-1 in the second study. In the third study, there was significantly enhanced tanning of the back in the MT-1 group, and this was maintained at least 3 weeks longer than the tanning in the sunlight-only controls, who required 50% more sun-exposure time for equivalent tanning. Main Outcome Measure: There were no pathologic findings at any UV-B or sun-exposed sites in any subject. Toxic effects due to MT-1 were minor, consisting of nausea and transient facial flushing. Conclusion: Melanotan-1 can be safely combined with UV-B light or sunlight and appears to act synergistically in the tanning response to light.
AB - Objective: Three phase 1 clinical trials of a superpotent melanotropic peptide, metanotan-1 (MT-1, or [Nle4-D-Phe7] α-melanocyte-stimulating hormone) were performed to demonstrate safety for MT-1 therapy combined with UV-B light or sunlight. Design: Open-label studies at 2 dose levels of MT-1 combined with small doses of UV-B to the neck or buttock or full sunlight to half of the back. Setting: Dermatology clinics at the Arizona Health Sciences Center, Tucson. Interventions: The first study randomized 4 subjects to MT-1 (0.08 mg/kg per day subcutaneously) and 4 subjects to injections of isotonic sodium chloride (9%) solution for 10 days, followed by neck irradiation with 3 times the minimal erythema dose (MED) of UV-B light. In the next study (n = 12), the MT-1 dosage was increased to 0.16 mg/kg per day for 10 days, with UV-B radiation (0.25-0.75 MED) given to a buttock site for 5 days during (n = 7) or after (n = 5) MT-1 administration. A final study randomized 8 subjects to 3 to 5 days of sunlight to half of the back or to sunlight plus 0.16 mg/kg of MT-1 for 5 days per week for 4 weeks. Results. Tanning in the first study was achieved in 3 of 4 subjects receiving MT-1, and these subjects also had 47% fewer sunburn cells at the irradiated neck site. More skin sites darkened with the higher dose of MT-1 in the second study. In the third study, there was significantly enhanced tanning of the back in the MT-1 group, and this was maintained at least 3 weeks longer than the tanning in the sunlight-only controls, who required 50% more sun-exposure time for equivalent tanning. Main Outcome Measure: There were no pathologic findings at any UV-B or sun-exposed sites in any subject. Toxic effects due to MT-1 were minor, consisting of nausea and transient facial flushing. Conclusion: Melanotan-1 can be safely combined with UV-B light or sunlight and appears to act synergistically in the tanning response to light.
UR - http://www.scopus.com/inward/record.url?scp=3142683968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142683968&partnerID=8YFLogxK
U2 - 10.1001/archderm.140.7.827
DO - 10.1001/archderm.140.7.827
M3 - Article
C2 - 15262693
AN - SCOPUS:3142683968
VL - 140
SP - 827
EP - 835
JO - JAMA Dermatology
JF - JAMA Dermatology
SN - 2168-6068
IS - 7
ER -